While there has been some speculation that GERN might be a buyout candidate, what about ACTC?
I suspect that they may be a much stronger candidate for buyout than GERN and there has been significant PPS activity over the past week or so. A $5 Billion buyout could reap some nice rewards for the ACTC PPS!!!
I think ACTC has a long road ahead. AMD trials will take years of review to make sure no cysts form. Even with a RS and their blood work going to trial they might have trouble staying independent. If they were to get bought out the #1 candidate in my book would be Biotime since they license ACTC's IPS cell IP and would also like to have Lanza on their team.
ACTC would make a nice subsidiary addition to Biotime in late 2013.
I could see ACTC as a take-out candidate because they are making great progress on a huge market.
But the $5 Billion tag is way farout. ACTC is valued at around $200Million right now, so if a suitor came in with even a $600 Million offer, it would be the CEO and BoDs fiduciary responsibility to take a deal that triples the value for shareholders. So $5B is way far off.
This is the Geron Stock Message Board. Please limit all discussions to topics pertinent to Geron Corporation and GERN stock, only. If you're inclined towards the discussion of companies other than Geron Corporation, please take those discussions the that company's stock message board.
Thank you very much.
Footnote: My Longe-Term Sentiment Disclosure of "Strong Buy" is directed toward the stock of Geron Corporation, only.
ryan: I don't quite agree with your estimate even though your math is very logical.
If you take a look at the potential demand for their products, worldwide, and what other companies have been bought for, I think that $5 Billion isn't that far from reasonable. Matter of fact from a market value, $5 Billion could be low.
I also think that the PPS could easily double or triple in the next 6 months or so. Let's face it, the stock was trading at about $.25 not that long ago (guess I could say a similar thing about GERN, LOL).